At CPHI Milan 2026, Dr. Peng Jiao, CEO of BiBo Pharma, will share his perspectives on the future of biomanufacturing in his keynote:
“Reshaping the World’s Landscape of Biomanufacturing: Scaling Sustainably for Global Impact”
📅 October 6, 2026 | 13:35–14:00
📍 Sustainability Spotlight Theatre, Fiera Milano
Hall 16 – Booth 16F60
Drawing on BiBo Pharma’s experience in large-scale biomanufacturing and engineering innovation, Dr. Jiao will explore how mega-scale capacity, innovative engineering, and global infrastructure can help build a more efficient, sustainable, and resilient biomanufacturing ecosystem.
01 | Healthcare Equity for 6 Billion
Today, access to biologic medicines remains limited for much of the world’s population.
BiBo Pharma is committed to breaking down cost barriers and expanding access to biologics—from approximately 1 billion people today to 6 billion by 2040.
02 | Mega-Scale Facilities
Scale can be a powerful driver of manufacturing efficiency and cost reduction.
BiBo Pharma has established 520,000 L of total biomanufacturing capacity, placing it among the world’s top five biologics CDMOs, including the world’s first 50,000 L bioreactor.
Looking ahead, BiBo Pharma plans to build a 1-million-liter mega-factory by 2030, with a long-term target of approximately $10/g manufacturing cost.
03 | Lean & Eco-Efficient Engineering
Scaling up should not mean consuming more resources.
Powered by its proprietary PanFlex® engineering system, BiBo Pharma aims to reduce facility construction time and CAPEX by approximately 50%, pursuing a leaner, more efficient, and lower-carbon approach to biomanufacturing infrastructure.
04 | Resilient Global Supply
The future of biomanufacturing requires not only greater capacity, but also a more resilient global supply network.
From high-yield manufacturing and sustainable infrastructure to cost optimization and global supply security, BiBo Pharma is exploring how the next generation of CDMOs can help drive the long-term growth of the global biologics industry—with scale, affordability, and sustainability at its core.
From 50,000 liters to 1 million liters.
From 1 billion people to 6 billion.
This is not simply a story about scale.
It is a vision for how biomanufacturing can help reshape global access to healthcare.
Join us in Milan on October 6 as we explore a critical question for the future of our industry:
How can biomanufacturing create greater impact with fewer resources?
